Reducing Sedentary Behaviour: A Novel Opportunity for Managing Comorbidity in MS?
Primary Purpose
Multiple Sclerosis
Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Sit Less with MS
Sponsored by

About this trial
This is an interventional other trial for Multiple Sclerosis focused on measuring Sedentary behaviour, Co-morbidity, Intervention
Eligibility Criteria
Inclusion Criteria
- confirmed diagnosis of MS of at least one-year duration.
- Expanded Disability Status Scale (EDSS) scores between 1 and 6.5.
- stable in terms of disease modifying drugs and rehabilitation over the previous 6 months.
- relapse free within the previous 3 months.
- physically inactive, defined as insufficiently active by Godin-Shephard Leisure-Time Physical Activity Questionnaire.
- able to walk with or without a walking aid for 10 meters.
Exclusion Criteria:
• other neurological problems besides MS or medically unstable to engage in the program.
Sites / Locations
- University of Alberta
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Sit Less with MS
Arm Description
The Sit Less with MS program is based on Social Cognitive Theory (SCT) and consists of strategies that will enable people with MS to 'sit less' by frequently interrupting sitting and 'move more' by replacing sitting with light-intensity activity during waking hours.
Outcomes
Primary Outcome Measures
Number of sedentary interruptions per day
Change in number of sedentary breaks from baseline to post-intervention and follow-up
Average sedentary time per day
Change in sedentary time from baseline to post-intervention and follow-up
Secondary Outcome Measures
Patient Determined Disease Steps (PDDS)
The PDDS will be used to track patient-reported impairment level from baseline to post-intervention and follow-up
Fatigue Severity Scale (FSS)
The FSS will be used to track patient-reported fatigue level from baseline to post-intervention and follow-up
Modified Fatigue Impact Scale
The Modified Fatigue Impact Scale will be used to track the impact of fatigue from baseline to post-intervention and follow-up
Symbol Digit Modality Test
The Symbol Digit Modality Test will be used to monitor cognitive status from baseline to post-intervention and follow-up
Hospital Anxiety and Depression Scale
The Hospital Anxiety and Depression Scale will be used to monitor level of depression from baseline to post-intervention and follow-up
Short Form McGill Pain Questionnaire
The Short Form McGill Pain Questionnaire will be used to monitor level of pain from baseline to post-intervention and follow-up
Pittsburgh Sleep Quality Questionnaire
The Pittsburgh Sleep Quality Questionnaire will be used to monitor sleep quality from baseline to post-intervention and follow-up
Godin-Shephard Leisure-Time Physical Activity Questionnaire
The Godin-Shephard Leisure-Time Physical Activity Questionnaire will be used to track self-reported physical activity level from baseline to post-intervention and follow-up
6-minute Walk Test
The 6-minute Walk test will be used to measure endurance from baseline to post-intervention and follow-up
10-meter Walk test
The 10-meter Walk test will be used to assess gait speed from baseline to post-intervention and follow-up
Short Physical Performance Battery
The Short Physical Performance Battery will be monitor balance, walking speed, and function from baseline to post-intervention and follow-up
Quality of Life (SF-36) Questionnaire
The Quality of Life (SF-36) Questionnaire will be used to monitor patient-reported quality of life from baseline to post-intervention and follow-up
Full Information
NCT ID
NCT03136744
First Posted
April 24, 2017
Last Updated
February 20, 2020
Sponsor
University of Alberta
Collaborators
Alberta Innovates Health Solutions
1. Study Identification
Unique Protocol Identification Number
NCT03136744
Brief Title
Reducing Sedentary Behaviour: A Novel Opportunity for Managing Comorbidity in MS?
Official Title
Reducing Sedentary Behaviour: A Novel Opportunity for Managing Comorbidity in MS?
Study Type
Interventional
2. Study Status
Record Verification Date
February 2020
Overall Recruitment Status
Completed
Study Start Date
February 3, 2018 (Actual)
Primary Completion Date
June 12, 2019 (Actual)
Study Completion Date
December 31, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Alberta
Collaborators
Alberta Innovates Health Solutions
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Activity recommendations for the general population and those with multiple sclerosis (MS) focus on the promotion of activity that has a moderate intensity - in other words, activity intense enough to breathe heavily and sweat. Most adults do not achieve the recommended 150 minutes of moderate-intensity activity per week. Even fewer persons with MS meet the recommendations. Those with MS often have problems with walking and fatigue, thus it is not difficult to understand that moderate intensity activity is challenging. Our study will test the feasibility of a new approach focusing on activity over the whole day - promoting light activity such as standing or walking around the house while reducing prolonged sitting (sedentary behaviour). This approach is supported by research evidence showing that too much sedentary time, especially prolonged bouts of sitting, is associated with health risk factors such as obesity and cholesterol level. Recent work with persons with MS confirms that prolonged sitting is a problem for this population and emphasises the potential importance of this approach.
This study tests the feasibility of an internet-based intervention designed to decrease sedentary behaviour and to increase upright time in people with MS.
Detailed Description
Background: The health risks of sedentary behaviour or 'sitting too much' for the general population are receiving widespread media attention, with bylines that include, "comfy chairs are killing us very softly" or "don't just sit there!" Others have suggested that sitting is the new smoking! This media attention reflects the exponential growth of research on sedentary behaviour in the last 10 years [1-4]. The investigators believe that learning more about sedentary behaviour and its health risks may be particularly relevant for those with multiple sclerosis (MS). People with MS are substantially less active than persons without MS and have co-morbidities such as walking disability and fatigue that may make achieving the 'typical' moderate to vigorous intensity exercise targets very difficult. The investigators will test a new approach to activity promotion that focuses on reducing sedentary behaviour and moving more during the day. This approach is likely to be more feasible and lead to more sustainable activity behaviour change in persons with MS. It's broad applicability - to persons with MS who move well, to those who need help to walk, and perhaps only walk at home - is a major strength of this new approach. In the end, if found to be effective, it could mean that a large majority of those with MS could receive the benefits of activity that they may be missing out on if only the usual moderate to vigorous activity programme is recommended.
Purpose: The purpose of this project is to test the feasibility of a sedentary behaviour intervention program on reducing sedentary behaviour and improving co-morbidities such as walking disability and fatigue in people with MS.
Methods: Forty persons with MS will be recruited from the community (mostly from Edmonton through our collaboration with the MS Society of Alberta) and the MS Clinic (University of Alberta Campus). The participants will be involved with the study for 24 weeks, including a 16-week intervention and an 8-week follow-up. The intervention includes two 8-week stages; 1) Sit Less Stage- Interruptions to prolonged sitting, and 2) Move More Stage- Reduction in total sitting time through replacing sitting with light physical activities.
Baseline testing will consist of demographic, anthropometric, impairment and functional testing. Subsequently, participants will be set up with an activity monitor (ActivPAL) to wear for 7 days. All outcomes, including those from the ActivPAL, will be assessed at three-time points: Baseline (Week 0), Post-intervention (Week 16), and Follow-up (Week 24). However, at mid-intervention (Week 8), data will be collected only from the ActivPAL activity monitor. A log book will be used by participants to record their wake-time and sleep-time and times when they didn't wear the monitor.
Intervention: Once baseline testing is completed, in the first week of intervention a Fitbit monitor will be attached to each participant's waist, and the participants will be asked to do the activities that they normally do every day. This information will be used to determine usual activity behaviour. Also, participants will be asked to wear the Fitbit throughout the entire 16 weeks of the intervention. A program manual will be provided to the participants to guide them throughout the 16 weeks of the intervention. In addition to the program manual, participants will receive (via email) a weekly newsletter that emphasises an aspect of behaviour change from social cognitive theory and Skype chats will be conducted as well.
Analysis: Most of the feasibility outcomes will be descriptive related to recruitment (e.g., number of participants enrolled/number of participants approached) and adherence to the intervention. Descriptive statistics (mean, SD) will be used to characterize the sample. A two-way mixed factor ANOVA will be used to determine whether there are main (time, level of disability) and/or interaction effects for two primary sedentary behaviour outcomes - the average number of sedentary interruptions, and average sedentary time per day. Effect sizes will be calculated for each of the sedentary behaviour and the co-morbidity outcomes. Where clinically meaningful change benchmarks are available, we will determine if changes achieved from the intervention were clinically significant.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Multiple Sclerosis
Keywords
Sedentary behaviour, Co-morbidity, Intervention
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
40 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Sit Less with MS
Arm Type
Experimental
Arm Description
The Sit Less with MS program is based on Social Cognitive Theory (SCT) and consists of strategies that will enable people with MS to 'sit less' by frequently interrupting sitting and 'move more' by replacing sitting with light-intensity activity during waking hours.
Intervention Type
Behavioral
Intervention Name(s)
Sit Less with MS
Intervention Description
The Sit Less with MS intervention has a total duration of 16 weeks and consists of two stages: sit less and move more stages. During the first stage (sit less), we will conduct coaching sessions with participants every week and the focus will be on interrupting their sitting time every 30 minutes. Facebook and Twitter will be also used to provide information and supplement coaching sessions. During the second stage, the focus will be on encouraging the participants to move more by replacing sitting with light intensity activities frequently throughout waking hours.
Primary Outcome Measure Information:
Title
Number of sedentary interruptions per day
Description
Change in number of sedentary breaks from baseline to post-intervention and follow-up
Time Frame
Baseline (week 0), post-intervention (week 16), and follow-up (week 24)
Title
Average sedentary time per day
Description
Change in sedentary time from baseline to post-intervention and follow-up
Time Frame
Baseline (week 0), post-intervention (week 16), and follow-up (week 24)
Secondary Outcome Measure Information:
Title
Patient Determined Disease Steps (PDDS)
Description
The PDDS will be used to track patient-reported impairment level from baseline to post-intervention and follow-up
Time Frame
Baseline (week 0), post-intervention (week 16), and follow-up (week 24)
Title
Fatigue Severity Scale (FSS)
Description
The FSS will be used to track patient-reported fatigue level from baseline to post-intervention and follow-up
Time Frame
Baseline (week 0), post-intervention (week 16), and follow-up (week 24)
Title
Modified Fatigue Impact Scale
Description
The Modified Fatigue Impact Scale will be used to track the impact of fatigue from baseline to post-intervention and follow-up
Time Frame
Baseline (week 0), post-intervention (week 16), and follow-up (week 24)
Title
Symbol Digit Modality Test
Description
The Symbol Digit Modality Test will be used to monitor cognitive status from baseline to post-intervention and follow-up
Time Frame
Baseline (week 0), post-intervention (week 16), and follow-up (week 24)
Title
Hospital Anxiety and Depression Scale
Description
The Hospital Anxiety and Depression Scale will be used to monitor level of depression from baseline to post-intervention and follow-up
Time Frame
Baseline (week 0), post-intervention (week 16), and follow-up (week 24)
Title
Short Form McGill Pain Questionnaire
Description
The Short Form McGill Pain Questionnaire will be used to monitor level of pain from baseline to post-intervention and follow-up
Time Frame
Baseline (week 0), post-intervention (week 16), and follow-up (week 24)
Title
Pittsburgh Sleep Quality Questionnaire
Description
The Pittsburgh Sleep Quality Questionnaire will be used to monitor sleep quality from baseline to post-intervention and follow-up
Time Frame
Baseline (week 0), post-intervention (week 16), and follow-up (week 24)
Title
Godin-Shephard Leisure-Time Physical Activity Questionnaire
Description
The Godin-Shephard Leisure-Time Physical Activity Questionnaire will be used to track self-reported physical activity level from baseline to post-intervention and follow-up
Time Frame
Baseline (week 0), post-intervention (week 16), and follow-up (week 24)
Title
6-minute Walk Test
Description
The 6-minute Walk test will be used to measure endurance from baseline to post-intervention and follow-up
Time Frame
Baseline (week 0), post-intervention (week 16), and follow-up (week 24)
Title
10-meter Walk test
Description
The 10-meter Walk test will be used to assess gait speed from baseline to post-intervention and follow-up
Time Frame
Baseline (week 0), post-intervention (week 16), and follow-up (week 24)
Title
Short Physical Performance Battery
Description
The Short Physical Performance Battery will be monitor balance, walking speed, and function from baseline to post-intervention and follow-up
Time Frame
Baseline (week 0), post-intervention (week 16), and follow-up (week 24)
Title
Quality of Life (SF-36) Questionnaire
Description
The Quality of Life (SF-36) Questionnaire will be used to monitor patient-reported quality of life from baseline to post-intervention and follow-up
Time Frame
Baseline (week 0), post-intervention (week 16), and follow-up (week 24)
Other Pre-specified Outcome Measures:
Title
Recruitment rate
Description
Number of participants enrolled out of total number approached
Time Frame
Follow-up (Week 24)
Title
Proportion of participants who completed the program [Adherence]
Description
Proportion of participants who completed the program
Time Frame
Follow-up (week 24)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria
confirmed diagnosis of MS of at least one-year duration.
Expanded Disability Status Scale (EDSS) scores between 1 and 6.5.
stable in terms of disease modifying drugs and rehabilitation over the previous 6 months.
relapse free within the previous 3 months.
physically inactive, defined as insufficiently active by Godin-Shephard Leisure-Time Physical Activity Questionnaire.
able to walk with or without a walking aid for 10 meters.
Exclusion Criteria:
• other neurological problems besides MS or medically unstable to engage in the program.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Patricia Manns, PhD
Organizational Affiliation
University of Alberta
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Robert Motl, PhD
Organizational Affiliation
University of Alabama at Birmingham
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Saeideh Aminian, PhD
Organizational Affiliation
University of Alberta
Official's Role
Study Director
Facility Information:
Facility Name
University of Alberta
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6G 2G4
Country
Canada
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
Participants de-identified data may be shared with our co-PI, Dr. Motl, with University of Alabama at Birmingham
IPD Sharing Time Frame
Data will be available for sharing after study completion by April 30, 2019.
IPD Sharing Access Criteria
Participants data will be de-identified prior to sharing with our co-PI, Dr. Motl with University of Alabama at Birmingham.
Citations:
PubMed Identifier
18252901
Citation
Healy GN, Dunstan DW, Salmon J, Cerin E, Shaw JE, Zimmet PZ, Owen N. Breaks in sedentary time: beneficial associations with metabolic risk. Diabetes Care. 2008 Apr;31(4):661-6. doi: 10.2337/dc07-2046. Epub 2008 Feb 5.
Results Reference
background
PubMed Identifier
21224291
Citation
Healy GN, Matthews CE, Dunstan DW, Winkler EA, Owen N. Sedentary time and cardio-metabolic biomarkers in US adults: NHANES 2003-06. Eur Heart J. 2011 Mar;32(5):590-7. doi: 10.1093/eurheartj/ehq451. Epub 2011 Jan 11.
Results Reference
background
PubMed Identifier
20577058
Citation
Owen N, Healy GN, Matthews CE, Dunstan DW. Too much sitting: the population health science of sedentary behavior. Exerc Sport Sci Rev. 2010 Jul;38(3):105-13. doi: 10.1097/JES.0b013e3181e373a2.
Results Reference
background
PubMed Identifier
22450936
Citation
van der Ploeg HP, Chey T, Korda RJ, Banks E, Bauman A. Sitting time and all-cause mortality risk in 222 497 Australian adults. Arch Intern Med. 2012 Mar 26;172(6):494-500. doi: 10.1001/archinternmed.2011.2174.
Results Reference
background
PubMed Identifier
34433359
Citation
Mehrabani G, Aminian S, Norton S, Motl RW, Manns PJ. Preliminary efficacy of the "SitLess with MS" intervention for changing sedentary behaviour, symptoms, and physical performance in multiple sclerosis. Disabil Rehabil. 2022 Oct;44(21):6374-6381. doi: 10.1080/09638288.2021.1966520. Epub 2021 Aug 25.
Results Reference
derived
PubMed Identifier
30940762
Citation
Aminian S, Motl RW, Rowley J, Manns PJ. Management of multiple sclerosis symptoms through reductions in sedentary behaviour: protocol for a feasibility study. BMJ Open. 2019 Apr 1;9(4):e026622. doi: 10.1136/bmjopen-2018-026622.
Results Reference
derived
Learn more about this trial
Reducing Sedentary Behaviour: A Novel Opportunity for Managing Comorbidity in MS?
We'll reach out to this number within 24 hrs